Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Roswell Park Comprehensive Cancer Center

Sites in Buffalo, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
528
Shown on this page
12
Current sort
Recently updated
Campus scope
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Roswell Park Comprehensive Cancer Center, Buffalo, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 385–396 of 528 matching trials with a site at Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

NCT06941389
Status at this site: Recruiting
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 20 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
Site status not listed — check the official record
View directory record Official record
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Navlimetostat, Gemcitabine, Nab-paclitaxel, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 1 Interventional

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT04978727
Site status not listed — check the official record
View directory record Official record
Conditions
Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand

NCT07102082
Status at this site: Recruiting
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Modified Risk - None, Modified Risk Claim
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Not applicable Interventional

Low GI Diet in Children and Adolescents With ALL

NCT03157323
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Obesity, Pediatric
Interventions
Low Glycemic Index Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
5
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT01167712
Site status not listed — check the official record
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Carboplatin, Computed Tomography, Paclitaxel, Therapeutic Conventional Surgery
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
559
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 374 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced MTAP-null Solid Tumors
Interventions
Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

NCT02275533
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231
Site status not listed — check the official record
View directory record Official record
Conditions
B Cell Precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
13
States / cities
Clovis, California • Duarte, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 7:18 PM EDT
Recruiting Not applicable Interventional

New York Better Breathing Study

NCT06869447
Status at this site: Recruiting
View directory record Official record
Conditions
Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Electronic Health Record Review, Medical Device Usage and Evaluation, Questionnaire Administration, Respiratory Muscle Training, Sham Intervention
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 7:18 PM EDT

About this Roswell Park Comprehensive Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Roswell Park Comprehensive Cancer Center in Buffalo, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.